Considering that nearly all primary neuroblastoma have an intact, wild-type p53 in conjunction with the improved potency and bioavailability of this latest generation MDM2 inhibitor, our data support the use of RG7388 for the treatment of high-risk neuroblastoma and potentially other p53 wild-type solid tumors. Here, TP53 is linked to neuroblastoma.